HR and breast neoplasm: Recent analyses reported from the RxPONDER,18 TAILORx,19 and MINDACT20 trials showed that among patients with HR+/HER2−, genomic low-risk breast tumors, younger (≤ 50 years of age) or premenopausal patients benefited from chemotherapy, whereas older (> 50 years of age) or postmenopausal patients did not.